Related Experiment Video
Updated: Jul 6, 2025
09:35
Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice
Published on: January 20, 2015
8.8K
Inhibition of 7α,26-dihydroxycholesterol biosynthesis promotes midbrain dopaminergic neuron development
James Hennegan1,2, Aled H Bryant1, Lauren Griffiths1,3,4
1Regenerative Neurobiology Laboratory, Swansea University Medical School, Institute of Life Science 1, Singleton Park, Swansea SA2 8PP, UK.
Iscience
|December 29, 2023
Summary
Elevated cholesterol metabolite 7α,26-diHC harms dopamine neuron development in Parkinson's disease (PD). Voriconazole, a CYP7B1 inhibitor, protects these neurons, suggesting potential therapeutic applications for PD.
Area of Science:
- Neuroscience
- Biochemistry
- Metabolomics
Background:
- Dysregulated cholesterol metabolism is implicated in neurodegenerative diseases.
- Elevated levels of 7α,26-dihydroxycholesterol (7α,26-diHC) were previously observed in Parkinson's disease (PD) cerebrospinal fluid.
Purpose of the Study:
- To investigate the role of 7α,26-diHC in the development and survival of midbrain dopamine (mDA) neurons.
- To explore the potential neuroprotective effects of CYP7B1 inhibition in the context of PD.
Main Methods:
- Utilized human embryonic stem cell (hESC)-derived and mouse progenitor cultures.
- Assessed the impact of 7α,26-diHC and voriconazole (a CYP7B1 inhibitor) on mDA neuron number and apoptosis.
- Evaluated the specificity of these effects by examining oculomotor neuron populations.
Main Results:
- 7α,26-diHC was found to induce apoptosis and reduce mDA neuron numbers in both hESC and mouse cultures.
- Voriconazole treatment increased mDA neuron numbers and prevented 7α,26-diHC-induced neurodegeneration.
- Neither 7α,26-diHC nor voriconazole affected Islet1+ oculomotor neuron counts, indicating specificity.
- Elevated 24(S),25-epoxycholesterol may partially mediate voriconazole's beneficial effects on mDA neurons.
Conclusions:
- 7α,26-diHC plays a detrimental role in mDA neuron development and survival.
- CYP7B1 inhibition, exemplified by voriconazole, demonstrates neuroprotective potential for mDA neurons.
- Azole CYP7B1 inhibitors represent a promising avenue for developing novel Parkinson's disease therapies.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
567
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
567
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
985
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
985
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.2K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.2K
01:24Parkinson's Disease: Treatment
273
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
273